Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney Disease Article Swipe
Yuki Hida
,
Teruhiko Imamura
,
Koichiro Kinugawa
,
Yuki Hida
,
Teruhiko Imamura
,
Koichiro Kinugawa
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/jcm14227997
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/jcm14227997
Background: Heart failure (HF) remains a major global health challenge with substantial morbidity, mortality, and healthcare burden. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has demonstrated cardiovascular and renal benefits in patients with diabetes mellitus (DM) and chronic kidney disease (CKD), as well as reduced HF events, in patients with HF with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). However, its efficacy and safety in patients with HF with reduced EF (HFrEF) or HFmrEF, DM, and CKD, remain unclear. Notably, finerenone is currently reimbursed only for DM and CKD but not for HF itself. Methods: We conducted a retrospective, single-center study of patients with HFrEF/HFmrEF who received finerenone between August 2022 and June 2025. Clinical data were obtained 6 months before, at baseline, and 6 months after the initiation of finerenone. The primary outcome was the change in serum NT pro-B-type natriuretic peptide (BNP). Results: Among 37 patients screened, 22 who initiated finerenone on a de novo basis were included. Median age was 75 years, 73% were male, and all had DM and CKD, which are current indications of finerenone. NT pro-BNP decreased significantly during the on-treatment period compared with the pre-treatment period (p < 0.001). Left ventricular end-diastolic diameter and left ventricular ejection fraction remained unchanged during the pre-treatment period but improved significantly during the on-treatment period (p < 0.001 for both). Renal function and serum potassium remained stable during the whole study period (p > 0.05 for both). Conclusions: In this real-world study of patients with HFrEF/HFmrEF complicated by DM and CKD, finerenone was associated with significant improvements in NT pro-BNP and cardiac remodeling indices without worsening renal function or hyperkalemia.
Related Topics
Concepts
Medicine
Ejection fraction
Internal medicine
Kidney disease
Heart failure
Diabetes mellitus
Cardiology
Renal function
Mineralocorticoid receptor
Natriuretic peptide
Brain natriuretic peptide
Heart disease
Incidence (geometry)
Prospective cohort study
Disease
Cardiac function curve
Comorbidity
Nephropathy
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/jcm14227997
- https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751
- OA Status
- gold
- References
- 21
- OpenAlex ID
- https://openalex.org/W7104632149
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W7104632149Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/jcm14227997Digital Object Identifier
- Title
-
Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney DiseaseWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-11Full publication date if available
- Authors
-
Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa, Yuki Hida, Teruhiko Imamura, Koichiro KinugawaList of authors in order
- Landing page
-
https://doi.org/10.3390/jcm14227997Publisher landing page
- PDF URL
-
https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751Direct OA link when available
- Concepts
-
Medicine, Ejection fraction, Internal medicine, Kidney disease, Heart failure, Diabetes mellitus, Cardiology, Renal function, Mineralocorticoid receptor, Natriuretic peptide, Brain natriuretic peptide, Heart disease, Incidence (geometry), Prospective cohort study, Disease, Cardiac function curve, Comorbidity, NephropathyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
21Number of works referenced by this work
Full payload
| id | https://openalex.org/W7104632149 |
|---|---|
| doi | https://doi.org/10.3390/jcm14227997 |
| ids.doi | https://doi.org/10.3390/jcm14227997 |
| ids.openalex | https://openalex.org/W7104632149 |
| fwci | 0.0 |
| type | article |
| title | Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney Disease |
| biblio.issue | 22 |
| biblio.volume | 14 |
| biblio.last_page | 7997 |
| biblio.first_page | 7997 |
| topics[0].id | https://openalex.org/T11839 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9442027807235718 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Hormonal Regulation and Hypertension |
| topics[1].id | https://openalex.org/T10198 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.03791347146034241 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Heart Failure Treatment and Management |
| topics[2].id | https://openalex.org/T12421 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.0035457781050354242 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2712 |
| topics[2].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[2].display_name | Adrenal Hormones and Disorders |
| is_xpac | False |
| apc_list.value | 2400 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2598 |
| apc_paid.value | 2400 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2598 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9786749482154846 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C78085059 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8117531538009644 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q641303 |
| concepts[1].display_name | Ejection fraction |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7011941075325012 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C2778653478 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6925645470619202 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1054718 |
| concepts[3].display_name | Kidney disease |
| concepts[4].id | https://openalex.org/C2778198053 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6805009841918945 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q181754 |
| concepts[4].display_name | Heart failure |
| concepts[5].id | https://openalex.org/C555293320 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6591437458992004 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[5].display_name | Diabetes mellitus |
| concepts[6].id | https://openalex.org/C164705383 |
| concepts[6].level | 1 |
| concepts[6].score | 0.6186730861663818 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[6].display_name | Cardiology |
| concepts[7].id | https://openalex.org/C159641895 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4825339615345001 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q108377937 |
| concepts[7].display_name | Renal function |
| concepts[8].id | https://openalex.org/C189135053 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4086511433124542 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3454531 |
| concepts[8].display_name | Mineralocorticoid receptor |
| concepts[9].id | https://openalex.org/C2775915353 |
| concepts[9].level | 3 |
| concepts[9].score | 0.31379434466362 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1571529 |
| concepts[9].display_name | Natriuretic peptide |
| concepts[10].id | https://openalex.org/C2775846464 |
| concepts[10].level | 3 |
| concepts[10].score | 0.3135722577571869 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q66360952 |
| concepts[10].display_name | Brain natriuretic peptide |
| concepts[11].id | https://openalex.org/C2780074459 |
| concepts[11].level | 2 |
| concepts[11].score | 0.28854742646217346 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q389735 |
| concepts[11].display_name | Heart disease |
| concepts[12].id | https://openalex.org/C61511704 |
| concepts[12].level | 2 |
| concepts[12].score | 0.27431705594062805 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1671857 |
| concepts[12].display_name | Incidence (geometry) |
| concepts[13].id | https://openalex.org/C188816634 |
| concepts[13].level | 2 |
| concepts[13].score | 0.27196648716926575 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q2113324 |
| concepts[13].display_name | Prospective cohort study |
| concepts[14].id | https://openalex.org/C2779134260 |
| concepts[14].level | 2 |
| concepts[14].score | 0.2636648416519165 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[14].display_name | Disease |
| concepts[15].id | https://openalex.org/C111566952 |
| concepts[15].level | 3 |
| concepts[15].score | 0.2620377838611603 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q1303462 |
| concepts[15].display_name | Cardiac function curve |
| concepts[16].id | https://openalex.org/C2779159551 |
| concepts[16].level | 2 |
| concepts[16].score | 0.2568507790565491 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q1414874 |
| concepts[16].display_name | Comorbidity |
| concepts[17].id | https://openalex.org/C2781184683 |
| concepts[17].level | 3 |
| concepts[17].score | 0.25381964445114136 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q1054718 |
| concepts[17].display_name | Nephropathy |
| keywords[0].id | https://openalex.org/keywords/ejection-fraction |
| keywords[0].score | 0.8117531538009644 |
| keywords[0].display_name | Ejection fraction |
| keywords[1].id | https://openalex.org/keywords/kidney-disease |
| keywords[1].score | 0.6925645470619202 |
| keywords[1].display_name | Kidney disease |
| keywords[2].id | https://openalex.org/keywords/heart-failure |
| keywords[2].score | 0.6805009841918945 |
| keywords[2].display_name | Heart failure |
| keywords[3].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[3].score | 0.6591437458992004 |
| keywords[3].display_name | Diabetes mellitus |
| keywords[4].id | https://openalex.org/keywords/renal-function |
| keywords[4].score | 0.4825339615345001 |
| keywords[4].display_name | Renal function |
| keywords[5].id | https://openalex.org/keywords/mineralocorticoid-receptor |
| keywords[5].score | 0.4086511433124542 |
| keywords[5].display_name | Mineralocorticoid receptor |
| keywords[6].id | https://openalex.org/keywords/natriuretic-peptide |
| keywords[6].score | 0.31379434466362 |
| keywords[6].display_name | Natriuretic peptide |
| language | en |
| locations[0].id | doi:10.3390/jcm14227997 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2737969411 |
| locations[0].source.issn | 2077-0383 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2077-0383 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Clinical Medicine |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Clinical Medicine |
| locations[0].landing_page_url | https://doi.org/10.3390/jcm14227997 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A2611986369 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Yuki Hida |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[0].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I42766147 |
| authorships[0].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | University of Toyama |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Yuki Hida |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[1].author.id | https://openalex.org/A2138089534 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7294-7637 |
| authorships[1].author.display_name | Teruhiko Imamura |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[1].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I42766147 |
| authorships[1].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | University of Toyama |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Teruhiko Imamura |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[2].author.id | https://openalex.org/A2569598000 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0009-8477 |
| authorships[2].author.display_name | Koichiro Kinugawa |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[2].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I42766147 |
| authorships[2].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | University of Toyama |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Koichiro Kinugawa |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[3].author.id | https://openalex.org/A2611986369 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Yuki Hida |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[3].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I42766147 |
| authorships[3].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | University of Toyama |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yuki Hida |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[4].author.id | https://openalex.org/A2138089534 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7294-7637 |
| authorships[4].author.display_name | Teruhiko Imamura |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[4].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I42766147 |
| authorships[4].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | University of Toyama |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Teruhiko Imamura |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[5].author.id | https://openalex.org/A2569598000 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0009-8477 |
| authorships[5].author.display_name | Koichiro Kinugawa |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I42766147 |
| authorships[5].affiliations[0].raw_affiliation_string | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I42766147 |
| authorships[5].institutions[0].ror | https://ror.org/https://ror.org/0445phv87 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I42766147 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | University of Toyama |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Koichiro Kinugawa |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-11T00:00:00 |
| display_name | Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney Disease |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-12T23:11:45.498971 |
| primary_topic.id | https://openalex.org/T11839 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9442027807235718 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Hormonal Regulation and Hypertension |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.3390/jcm14227997 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2737969411 |
| best_oa_location.source.issn | 2077-0383 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2077-0383 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Clinical Medicine |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Clinical Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.3390/jcm14227997 |
| primary_location.id | doi:10.3390/jcm14227997 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2737969411 |
| primary_location.source.issn | 2077-0383 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2077-0383 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Clinical Medicine |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/2077-0383/14/22/7997/pdf?version=1762860751 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Clinical Medicine |
| primary_location.landing_page_url | https://doi.org/10.3390/jcm14227997 |
| publication_date | 2025-11-11 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3193598686, https://openalex.org/W2906115286, https://openalex.org/W4390544691, https://openalex.org/W2323458614, https://openalex.org/W2164705414, https://openalex.org/W4413869652, https://openalex.org/W2111945961, https://openalex.org/W1850056200, https://openalex.org/W4386204439, https://openalex.org/W2775999271, https://openalex.org/W3094429645, https://openalex.org/W3194763937, https://openalex.org/W4402101139, https://openalex.org/W4413113539, https://openalex.org/W4402101440, https://openalex.org/W4408901310, https://openalex.org/W2152094259, https://openalex.org/W3093851112, https://openalex.org/W2134617609, https://openalex.org/W2074576032, https://openalex.org/W2152072062 |
| referenced_works_count | 21 |
| abstract_inverted_index.6 | 119, 125 |
| abstract_inverted_index.a | 5, 18, 98, 155 |
| abstract_inverted_index.(p | 194, 219, 236 |
| abstract_inverted_index.22 | 150 |
| abstract_inverted_index.37 | 147 |
| abstract_inverted_index.75 | 164 |
| abstract_inverted_index.DM | 87, 172, 252 |
| abstract_inverted_index.EF | 71 |
| abstract_inverted_index.HF | 46, 51, 68, 93 |
| abstract_inverted_index.In | 242 |
| abstract_inverted_index.NT | 140, 181, 262 |
| abstract_inverted_index.We | 96 |
| abstract_inverted_index.as | 42, 44 |
| abstract_inverted_index.at | 122 |
| abstract_inverted_index.by | 251 |
| abstract_inverted_index.de | 156 |
| abstract_inverted_index.in | 31, 48, 65, 138, 261 |
| abstract_inverted_index.is | 82 |
| abstract_inverted_index.of | 102, 130, 179, 246 |
| abstract_inverted_index.on | 154 |
| abstract_inverted_index.or | 54, 73, 272 |
| abstract_inverted_index.73% | 166 |
| abstract_inverted_index.CKD | 89 |
| abstract_inverted_index.DM, | 75 |
| abstract_inverted_index.The | 132 |
| abstract_inverted_index.age | 162 |
| abstract_inverted_index.all | 170 |
| abstract_inverted_index.and | 14, 28, 37, 63, 76, 88, 112, 124, 169, 173, 201, 226, 253, 264 |
| abstract_inverted_index.are | 176 |
| abstract_inverted_index.but | 90, 212 |
| abstract_inverted_index.for | 86, 92, 222, 239 |
| abstract_inverted_index.had | 171 |
| abstract_inverted_index.has | 25 |
| abstract_inverted_index.its | 61 |
| abstract_inverted_index.not | 91 |
| abstract_inverted_index.the | 128, 136, 186, 191, 209, 216, 232 |
| abstract_inverted_index.was | 135, 163, 256 |
| abstract_inverted_index.who | 106, 151 |
| abstract_inverted_index.> | 237 |
| abstract_inverted_index.< | 195, 220 |
| abstract_inverted_index.(DM) | 36 |
| abstract_inverted_index.(HF) | 3 |
| abstract_inverted_index.0.05 | 238 |
| abstract_inverted_index.2022 | 111 |
| abstract_inverted_index.CKD, | 77, 174, 254 |
| abstract_inverted_index.June | 113 |
| abstract_inverted_index.Left | 197 |
| abstract_inverted_index.data | 116 |
| abstract_inverted_index.left | 202 |
| abstract_inverted_index.novo | 157 |
| abstract_inverted_index.only | 85 |
| abstract_inverted_index.this | 243 |
| abstract_inverted_index.well | 43 |
| abstract_inverted_index.were | 117, 159, 167 |
| abstract_inverted_index.with | 10, 33, 50, 52, 67, 69, 104, 190, 248, 258 |
| abstract_inverted_index.0.001 | 221 |
| abstract_inverted_index.2025. | 114 |
| abstract_inverted_index.Among | 146 |
| abstract_inverted_index.Heart | 1 |
| abstract_inverted_index.Renal | 224 |
| abstract_inverted_index.after | 127 |
| abstract_inverted_index.basis | 158 |
| abstract_inverted_index.major | 6 |
| abstract_inverted_index.male, | 168 |
| abstract_inverted_index.novel | 19 |
| abstract_inverted_index.renal | 29, 270 |
| abstract_inverted_index.serum | 139, 227 |
| abstract_inverted_index.study | 101, 234, 245 |
| abstract_inverted_index.which | 175 |
| abstract_inverted_index.whole | 233 |
| abstract_inverted_index.(BNP). | 144 |
| abstract_inverted_index.(CKD), | 41 |
| abstract_inverted_index.(MRA), | 24 |
| abstract_inverted_index.August | 110 |
| abstract_inverted_index.Median | 161 |
| abstract_inverted_index.both). | 223, 240 |
| abstract_inverted_index.change | 137 |
| abstract_inverted_index.during | 185, 208, 215, 231 |
| abstract_inverted_index.global | 7 |
| abstract_inverted_index.health | 8 |
| abstract_inverted_index.kidney | 39 |
| abstract_inverted_index.mildly | 55 |
| abstract_inverted_index.months | 120, 126 |
| abstract_inverted_index.period | 188, 193, 211, 218, 235 |
| abstract_inverted_index.remain | 78 |
| abstract_inverted_index.safety | 64 |
| abstract_inverted_index.stable | 230 |
| abstract_inverted_index.years, | 165 |
| abstract_inverted_index.(HFrEF) | 72 |
| abstract_inverted_index.0.001). | 196 |
| abstract_inverted_index.HFmrEF, | 74 |
| abstract_inverted_index.before, | 121 |
| abstract_inverted_index.between | 109 |
| abstract_inverted_index.burden. | 16 |
| abstract_inverted_index.cardiac | 265 |
| abstract_inverted_index.chronic | 38 |
| abstract_inverted_index.current | 177 |
| abstract_inverted_index.disease | 40 |
| abstract_inverted_index.events, | 47 |
| abstract_inverted_index.failure | 2 |
| abstract_inverted_index.indices | 267 |
| abstract_inverted_index.itself. | 94 |
| abstract_inverted_index.outcome | 134 |
| abstract_inverted_index.peptide | 143 |
| abstract_inverted_index.primary | 133 |
| abstract_inverted_index.pro-BNP | 182, 263 |
| abstract_inverted_index.reduced | 45, 56, 70 |
| abstract_inverted_index.remains | 4 |
| abstract_inverted_index.without | 268 |
| abstract_inverted_index.Clinical | 115 |
| abstract_inverted_index.However, | 60 |
| abstract_inverted_index.Methods: | 95 |
| abstract_inverted_index.Notably, | 80 |
| abstract_inverted_index.Results: | 145 |
| abstract_inverted_index.benefits | 30 |
| abstract_inverted_index.compared | 189 |
| abstract_inverted_index.diabetes | 34 |
| abstract_inverted_index.diameter | 200 |
| abstract_inverted_index.efficacy | 62 |
| abstract_inverted_index.ejection | 57, 204 |
| abstract_inverted_index.fraction | 58, 205 |
| abstract_inverted_index.function | 225, 271 |
| abstract_inverted_index.improved | 213 |
| abstract_inverted_index.mellitus | 35 |
| abstract_inverted_index.obtained | 118 |
| abstract_inverted_index.patients | 32, 49, 66, 103, 148, 247 |
| abstract_inverted_index.received | 107 |
| abstract_inverted_index.receptor | 22 |
| abstract_inverted_index.remained | 206, 229 |
| abstract_inverted_index.unclear. | 79 |
| abstract_inverted_index.baseline, | 123 |
| abstract_inverted_index.challenge | 9 |
| abstract_inverted_index.conducted | 97 |
| abstract_inverted_index.currently | 83 |
| abstract_inverted_index.decreased | 183 |
| abstract_inverted_index.included. | 160 |
| abstract_inverted_index.initiated | 152 |
| abstract_inverted_index.potassium | 228 |
| abstract_inverted_index.preserved | 53 |
| abstract_inverted_index.screened, | 149 |
| abstract_inverted_index.unchanged | 207 |
| abstract_inverted_index.worsening | 269 |
| abstract_inverted_index.antagonist | 23 |
| abstract_inverted_index.associated | 257 |
| abstract_inverted_index.finerenone | 81, 108, 153, 255 |
| abstract_inverted_index.healthcare | 15 |
| abstract_inverted_index.initiation | 129 |
| abstract_inverted_index.morbidity, | 12 |
| abstract_inverted_index.mortality, | 13 |
| abstract_inverted_index.pro-B-type | 141 |
| abstract_inverted_index.real-world | 244 |
| abstract_inverted_index.reimbursed | 84 |
| abstract_inverted_index.remodeling | 266 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.Finerenone, | 17 |
| abstract_inverted_index.complicated | 250 |
| abstract_inverted_index.finerenone. | 131, 180 |
| abstract_inverted_index.indications | 178 |
| abstract_inverted_index.natriuretic | 142 |
| abstract_inverted_index.significant | 259 |
| abstract_inverted_index.substantial | 11 |
| abstract_inverted_index.ventricular | 198, 203 |
| abstract_inverted_index.Conclusions: | 241 |
| abstract_inverted_index.HFrEF/HFmrEF | 105, 249 |
| abstract_inverted_index.demonstrated | 26 |
| abstract_inverted_index.improvements | 260 |
| abstract_inverted_index.on-treatment | 187, 217 |
| abstract_inverted_index.end-diastolic | 199 |
| abstract_inverted_index.hyperkalemia. | 273 |
| abstract_inverted_index.non-steroidal | 20 |
| abstract_inverted_index.pre-treatment | 192, 210 |
| abstract_inverted_index.significantly | 184, 214 |
| abstract_inverted_index.single-center | 100 |
| abstract_inverted_index.cardiovascular | 27 |
| abstract_inverted_index.retrospective, | 99 |
| abstract_inverted_index.(HFpEF/HFmrEF). | 59 |
| abstract_inverted_index.mineralocorticoid | 21 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| citation_normalized_percentile.value | 0.79777526 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |